How Long Does Mounjaro Take to Work — and How Will You Know?

Why the first four weeks feel slow, and why that's by design

The 2.5mg starting dose exists for one reason: to let your body adjust to a new medicine rather than to produce weight loss immediately. At this level, tirzepatide's effects on appetite are noticeable to some people (meals feel like enough sooner, snacking urges settle) but the scale may barely move. That is entirely expected.

Your prescriber sets the titration schedule. The licensed approach moves through 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg, typically spending four weeks at each level. The clinical reason for this gradual progression is tolerability: the gastrointestinal side effects that some people experience (nausea, loose stools, indigestion) are most manageable when the dose increases slowly. Rushing through doses does not accelerate results; it tends to increase discomfort.

A question our prescribers hear most weeks is whether something is wrong because the first pen produced almost no change on the scales. The honest answer is that nothing is wrong. The NHS's patient guidance on tirzepatide confirms that weight loss builds progressively as doses increase, the early phase is preparation, not failure.

One thing that does change early: food noise. Many people describe a quietening of persistent thoughts about eating within the first two weeks, and if you are curious about how long tirzepatide takes to work at each stage of treatment, that detail is covered in full. That shift, while not a number on the scales, is the medicine beginning to work.

The middle phase: where most of the weight loss happens

Between roughly weeks four and twenty-four (as doses move through 5mg, 7.5mg and 10mg) most people see the clearest sustained weight reduction. The mechanism here is Mounjaro's dual activation of both GIP and GLP-1 receptors, which together slow gastric emptying, increase feelings of fullness and influence how the brain processes hunger signals. Understanding how Mounjaro works in more depth can help set realistic expectations for this phase.

Clinical trial results from SURMOUNT-1 (published in the New England Journal of Medicine) recorded an average body-weight reduction of around 20–21% at the 15mg dose over 72 weeks. That headline figure is achievable for many, but it accumulates gradually, not in a straight line. There will be weeks the scale does not move. There will be weeks it drops more than expected. Neither necessarily means anything has changed about the medicine's effect.

Protein intake, staying hydrated and keeping some form of regular movement going all support the process. A prescriber or dietitian can advise on specifics, general guidance lives with NHS healthy weight resources, but personalised plans belong with your clinical team.

Some people also wonder about the best time to begin treatment relative to their own schedule and lifestyle commitments, worth thinking through before the first pen.

Reaching the maintenance dose: what the evidence says about the longer view

If you reach 15mg and continue on it, you are in the phase the trials were largely built to measure. The SURMOUNT-1 data shows that weight loss continues for most participants well into the second year at maintenance dose, it does not simply plateau at month three.

NICE's appraisal of tirzepatide, TA1026, includes the clinical benchmark that treatment should be reviewed if less than 5% of body weight has been lost after six months at the highest tolerated dose. This is the threshold for deciding whether to continue, it is a clinical review point, not an automatic stop. Your prescriber makes that call with you.

People who previously used a different GLP-1 medicine sometimes ask about whether Mounjaro works if a first treatment didn't, the mechanisms differ enough that it is a reasonable clinical question, and one worth raising at consultation.

Cost is a real consideration over months of treatment; the context around Mounjaro's UK pricing has shifted since late 2025, and understanding it helps with planning. At nume, treatment is priced transparently and includes clinical review, prescription and free next-working-day delivery, see our treatment options page for current pricing.

When to flag something to your prescriber

Tirzepatide is a Black Triangle medicine, which means the MHRA monitors it closely. Most side effects are mild and ease within days of a new dose. Some need prompt attention.

Severe, persistent stomach pain that radiates toward the back (with or without vomiting) should be assessed urgently, as it can signal acute pancreatitis. Gallbladder symptoms, signs of significant dehydration from ongoing vomiting or diarrhoea, and any allergic reaction all warrant the same response: contact a healthcare professional or NHS 111 without delay, and do not simply wait for the next scheduled check-in.

The first day on Mounjaro can prompt questions about injection technique and what to watch for, it is worth knowing the signs before you start. Suspected side effects can be reported to the MHRA through the Yellow Card scheme.

If you are thinking about starting treatment and want to understand eligibility, our prescribers are a good first conversation. Check your eligibility through a free consultation with the nume team, reviewed the same day by a GPhC-registered prescriber.